Morbid Obesity in Type 1 Diabetes: Management After GLP-1 RA–Based Therapy Has Not Achieved Adequate Weight Reduction

This protocol applies to adults with type 1 diabetes and obesity (BMI ≥30.0 kg/m², or ≥27.5 kg/m² in Asian American individuals) in whom a GLP-1 receptor agonist–based regimen did not achieve the required reductions in weight, A1C, and insulin requirements.

Clinical Scenario

Adults with type 1 diabetes and a BMI ≥30.0 kg/m² (or ≥27.5 kg/m² in Asian American individuals) are candidates for the same structured obesity management strategies available to the general adult population. Insulin dependence in the setting of significant excess adiposity defines a distinct management challenge.

Prior Line — Escalation Criteria

GLP-1 RA–based therapy (a GLP-1 receptor agonist or a dual GIP and GLP-1 receptor agonist) was the initial step, initiated with cautious titration and close monitoring of insulin requirements, hypoglycemia, and ketones. Escalation to the next line is indicated when adequate weight reduction, improvement in A1C, and lower insulin requirements were not achieved.

Next-Line Approach (Partial Overview)

A surgical approach to obesity management is among the highly individualized options evaluated at this stage, following careful multidisciplinary assessment and counseling. The primary clinical target is a meaningful reduction in BMI from the preoperative value. The complete eligibility pathway, evaluation requirements, and management details are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.2337/dc26-S008

Apply obesity management strategies used in the general adult population, including GLP-1 RA–based therapy B and metabolic surgery, C to adults with type 1 diabetes who have obesity (BMI ≥30.0 kg/m², or ≥27.5 kg/m² in Asian American individuals).

Metabolic surgery represents a highly individualized option for management of obesity in people with type 1 diabetes.

In a retrospective analysis of 17 bariatric surgery studies that included 107 individuals with type 1 diabetes, 65% of whom underwent RYGB, the average achieved postoperative BMI was 31 kg/m² (reduced from an average preoperative BMI of 41 kg/m²) over an observation period of 1.5–5 years.

View source ↗